Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica Coutre, S., Tedeschi, A., Robak, T., Barr, P. M., Owen, C., Bairey, O., Burger, J., Zhou, C., Styles, L., James, D. F., Kipps, T. J. 2018; 103 (6): e249–e251
View details for PubMedID 29170253